-
1
-
-
84971236837
-
Oncogenes and suppressor genes: genetic control of cancer
-
In: Goldman L, Ausiello D, eds. 22nd ed. Philadelphia: W.B. Saunders
-
Liu ET. Oncogenes and suppressor genes: genetic control of cancer. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W.B. Saunders, 2004:1108-1116.
-
(2004)
Cecil Textbook of Medicine
, pp. 1108-1116
-
-
Liu, E.T.1
-
2
-
-
84971203121
-
Principles of cancer therapy
-
In: Goldman L, Ausiello D, eds. 22nd ed. Philadelphia: W.B. Saunders
-
Bertino JR, Hait W. Principles of cancer therapy. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W.B. Saunders, 2004:1137-1150.
-
(2004)
Cecil Textbook of Medicine
, pp. 1137-1150
-
-
Bertino, J.R.1
Hait, W.2
-
3
-
-
80053483803
-
Cancer treatment and chemotherapy
-
In: DiPiro JT, Talbert RL, Yee GC, et al., eds. 7th ed. New York: McGraw-Hill
-
Medina PJ, Fausel C. Cancer treatment and chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 7th ed. New York: McGraw-Hill, 2008:2085-2119.
-
(2008)
Pharmacotherapy: A Pathophysiologic Approach
, pp. 2085-2119
-
-
Medina, P.J.1
Fausel, C.2
-
4
-
-
33645635719
-
Antineoplastic agents
-
In: Brunton LL, Lazo JS, Parker KL, eds. 11th ed. New York: McGraw Hill
-
Chabner BA, Amrein PC, Drucker BJ, et al. Antineoplastic agents. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw Hill, 2005:1319-1321.
-
(2005)
Goodman & Gilman's The Pharmacological Basis of Therapeutics
, pp. 1319-1321
-
-
Chabner, B.A.1
Amrein, P.C.2
Drucker, B.J.3
-
5
-
-
84928208788
-
Invasion and metastases
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Minn AJ, Massague J. Invasion and metastases. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:117-118.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 117-118
-
-
Minn, A.J.1
Massague, J.2
-
6
-
-
0017401820
-
The historical development of cancer chemotherapy
-
Burchenal JH. The historical development of cancer chemotherapy. Semin Oncol 1977;4:135-146.
-
(1977)
Semin Oncol
, vol.4
, pp. 135-146
-
-
Burchenal, J.H.1
-
7
-
-
34147147676
-
General review of cancer therapy
-
In: Moulton FR, ed. Washington, DC: AAAS
-
Woglom WH. General review of cancer therapy. In: Moulton FR, ed. Approaches to Tumor Chemotherapy. Washington, DC: AAAS, 1947:1.
-
(1947)
Approaches to Tumor Chemotherapy.
, pp. 1
-
-
Woglom, W.H.1
-
8
-
-
84971339566
-
Pharmacology of cancer chemotherapy: drug development
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Sznol M. Pharmacology of cancer chemotherapy: drug development. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:385-392.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 385-392
-
-
Sznol, M.1
-
9
-
-
84971315765
-
Telomeres, telomerase, and cell immortalization
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Wong K-K, Sharpless NE, Depinho RA. Telomeres, telomerase, and cell immortalization. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:53-66.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 53-66
-
-
Wong, K.-K.1
Sharpless, N.E.2
Depinho, R.A.3
-
10
-
-
84971252552
-
Pharmacogenomics
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
El-Khoueiry A, Lenz HJ. Pharmacogenomics. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:402-407.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 402-407
-
-
El-Khoueiry, A.1
Lenz, H.J.2
-
11
-
-
0003964363
-
-
Accessed December
-
American Cancer Society. Cancer facts and figures, 2010. http://www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/ acspc-026238.pdf. Accessed December 2, 2010.
-
(2010)
Cancer facts figures
, vol.2
, pp. 2010
-
-
-
12
-
-
65249088196
-
Epidemiology of cancer
-
In: Goldman L, Ausiello D, eds. 22nd ed. Philadelphia: W.B. Saunders
-
Blot WJ. Epidemiology of cancer. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W.B. Saunders, 2004:1116-1120.
-
(2004)
Cecil Textbook of Medicine
, pp. 1116-1120
-
-
Blot, W.J.1
-
13
-
-
84971252555
-
-
Accessed December
-
The signs of cancer. http://www.radoncgroup.com/signsofcancer.pdf. Accessed December 16, 2010.
-
(2010)
, vol.16
-
-
-
14
-
-
84971252554
-
Etiology of cancer: viruses: RNA viruses
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Buchschacher GL Jr, Wong-Staal F. Etiology of cancer: viruses: RNA viruses. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:169-177.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 169-177
-
-
Buchschacher G.L, Jr.1
Wong-Staal, F.2
-
15
-
-
84971212926
-
Etiology of cancer: viruses: DNA viruses
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Howley PM, Ganem D, Kieff E. Etiology of cancer: viruses: DNA viruses. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:177-189.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 177-189
-
-
Howley, P.M.1
Ganem, D.2
Kieff, E.3
-
16
-
-
0032849465
-
The chemistry of the metabolites of cyclophosphamide
-
Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 1999;5:627-643.
-
(1999)
Curr Pharm Des
, vol.5
, pp. 627-643
-
-
Ludeman, S.M.1
-
17
-
-
0017360366
-
Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro
-
Goldenberg GJ, Lee M, Lam HY, et al. Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer Res 1977;37:755-760.
-
(1977)
Cancer Res
, vol.37
, pp. 755-760
-
-
Goldenberg, G.J.1
Lee, M.2
Lam, H.Y.3
-
18
-
-
77954663766
-
Bendamustine: something old, something new
-
Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413-423.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 413-423
-
-
Tageja, N.1
Nagi, J.2
-
19
-
-
77953441848
-
Bendamustine: new perspective for an old drug in lymphoproliferative disorders
-
Montillo M, Ricci F, Tedeschi A, et al. Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev Hematol 2010;3:131-148.
-
(2010)
Expert Rev Hematol
, vol.3
, pp. 131-148
-
-
Montillo, M.1
Ricci, F.2
Tedeschi, A.3
-
20
-
-
77954843368
-
Oxazaphosphorines: new therapeutic strategies for an old class of drugs
-
Giraud B, Herbert G, Deroussent A, et al. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol 2010;6:919-938.
-
(2010)
Expert Opin Drug Metab Toxicol
, vol.6
, pp. 919-938
-
-
Giraud, B.1
Herbert, G.2
Deroussent, A.3
-
21
-
-
0033951849
-
Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
-
Huang A, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59:961-972.
-
(2000)
Biochem Pharmacol
, vol.59
, pp. 961-972
-
-
Huang, A.1
Roy, P.2
Waxman, D.J.3
-
22
-
-
0024334410
-
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo
-
Lind MJ, McGown AT, Hadfield JA, et al. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 1989;38:1835-1840.
-
(1989)
Biochem Pharmacol
, vol.38
, pp. 1835-1840
-
-
Lind, M.J.1
McGown, A.T.2
Hadfield, J.A.3
-
23
-
-
0029008311
-
Acrolein mercapturates: synthesis, characterization and assessment of their role in the bladder toxicity of cyclophosphamide
-
Ramu K, Fraiser LH, Mamiya B, et al. Acrolein mercapturates: synthesis, characterization and assessment of their role in the bladder toxicity of cyclophosphamide. Chem Res Toxicol 1995;8:515-524.
-
(1995)
Chem Res Toxicol
, vol.8
, pp. 515-524
-
-
Ramu, K.1
Fraiser, L.H.2
Mamiya, B.3
-
24
-
-
0030273743
-
Studies on the basis for the toxicity of acrolein mercapturates
-
Ramu K, Perry CS, Ahmed T, et al. Studies on the basis for the toxicity of acrolein mercapturates. Toxicol Appl Pharmacol 1996;140;487-498.
-
(1996)
Toxicol Appl Pharmacol
, vol.140
, pp. 487-498
-
-
Ramu, K.1
Perry, C.S.2
Ahmed, T.3
-
25
-
-
0031041912
-
Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo
-
Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997;17:75-79.
-
(1997)
J Appl Toxicol
, vol.17
, pp. 75-79
-
-
Springate, J.E.1
-
26
-
-
0033051029
-
Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
-
Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999;27:655-666.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 655-666
-
-
Roy, P.1
Yu, L.J.2
Crespi, C.L.3
-
27
-
-
0034711384
-
Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites
-
Woodland D, Ito S, Granvil CP, et al. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-117.
-
(2000)
Life Sci
, vol.68
, pp. 109-117
-
-
Woodland, D.1
Ito, S.2
Granvil, C.P.3
-
28
-
-
59649125837
-
New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity
-
Storme T, Deroussent A, Mercier L, et al. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity. J Pharmacol Exp Ther 2009;328:598-609.
-
(2009)
J Pharmacol Exp Ther
, vol.328
, pp. 598-609
-
-
Storme, T.1
Deroussent, A.2
Mercier, L.3
-
29
-
-
77955771137
-
Some physicochemical properties of the antitumor drug thiotepa and its metabolite tepa as obtained by density functional theory (DFT) calculations
-
Kheffache D, Ouameraldi O. Some physicochemical properties of the antitumor drug thiotepa and its metabolite tepa as obtained by density functional theory (DFT) calculations. J Mol Model 2010;16:1383-1390.
-
(2010)
J Mol Model
, vol.16
, pp. 1383-1390
-
-
Kheffache, D.1
Ouameraldi, O.2
-
30
-
-
0022898266
-
DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitroso compounds
-
Eisenbrand G, Muller N, Denkel E, et al. DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitroso compounds. J Cancer Res Clin Oncol 1986;112:196-204.
-
(1986)
J Cancer Res Clin Oncol
, vol.112
, pp. 196-204
-
-
Eisenbrand, G.1
Muller, N.2
Denkel, E.3
-
31
-
-
58849156422
-
BCNU sequestration by metallothioneines may contribute to resistance in a medulloblastoma cell line
-
Bacolod MD, Fehdrau R, Johnson SP, et al. BCNU sequestration by metallothioneines may contribute to resistance in a medulloblastoma cell line. Cancer Chemother Pharmacol 2009;63:753-758.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 753-758
-
-
Bacolod, M.D.1
Fehdrau, R.2
Johnson, S.P.3
-
32
-
-
0030866921
-
DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance
-
Kyrtopoulos SA, Anderson LM, Chhabra SK, et al. DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer Detect Prev 1997;21:391-405.
-
(1997)
Cancer Detect Prev
, vol.21
, pp. 391-405
-
-
Kyrtopoulos, S.A.1
Anderson, L.M.2
Chhabra, S.K.3
-
33
-
-
0036015562
-
Tumour cytochrome P450 and drug activation
-
Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-1347.
-
(2002)
Curr Pharm Des
, vol.8
, pp. 1335-1347
-
-
Patterson, L.H.1
Murray, G.I.2
-
34
-
-
0021992540
-
Metabolic activation of the terminal N-methyl group of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine)
-
Moloney SJ, Wiebkin P, Cummings SW, et al. Metabolic activation of the terminal N-methyl group of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine). Carcinogenesis 1985;6:397-401.
-
(1985)
Carcinogenesis
, vol.6
, pp. 397-401
-
-
Moloney, S.J.1
Wiebkin, P.2
Cummings, S.W.3
-
35
-
-
0020630971
-
Studies on the pathway of methane formation from procarbazine, a 2-methylbenzylhydrazine derivative, by rat liver microsomes
-
Moloney SJ, Prough RA. Studies on the pathway of methane formation from procarbazine, a 2-methylbenzylhydrazine derivative, by rat liver microsomes. Arch Biochem Biophys 1983;221:577-584.
-
(1983)
Arch Biochem Biophys
, vol.221
, pp. 577-584
-
-
Moloney, S.J.1
Prough, R.A.2
-
36
-
-
0031918603
-
Metabolism of dacarbazine by rat liver microsomes: contribution of CYP1A enzymes to dacarbazine N-demethylation
-
Yamagata S, Ohmori S, Suzuki N, et al. Metabolism of dacarbazine by rat liver microsomes: contribution of CYP1A enzymes to dacarbazine N-demethylation. Drug Metab Dispos 1998;26:379-382.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 379-382
-
-
Yamagata, S.1
Ohmori, S.2
Suzuki, N.3
-
37
-
-
78049241028
-
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
-
Cai W, Maldonado NV, Cui W, et al. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer 2010;103:1369-1379.
-
(2010)
Br J Cancer
, vol.103
, pp. 1369-1379
-
-
Cai, W.1
Maldonado, N.V.2
Cui, W.3
-
38
-
-
0029072902
-
The role of N-(hydroxymethyl) melamines as antitumour agents: mechanism of action studies
-
Coley HM, Brooks N, Phillips DH, et al. The role of N-(hydroxymethyl) melamines as antitumour agents: mechanism of action studies. Biochem Pharmacol 1995;9:1203-1212.
-
(1995)
Biochem Pharmacol
, vol.9
, pp. 1203-1212
-
-
Coley, H.M.1
Brooks, N.2
Phillips, D.H.3
-
39
-
-
0025726126
-
Hexamethylmelamine: pharmacology and mechanism of action
-
Ames MM. Hexamethylmelamine: pharmacology and mechanism of action. Can Treat Rev 1991;18(Suppl A):3-14.
-
(1991)
Can Treat Rev
, vol.18
, pp. 3-14
-
-
Ames, M.M.1
-
40
-
-
77949630054
-
Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation
-
Deng SJ, Wang S, Cao J, et al. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug Deliv 2010;17:164-170.
-
(2010)
Drug Deliv
, vol.17
, pp. 164-170
-
-
Deng, S.J.1
Wang, S.2
Cao, J.3
-
41
-
-
0025801796
-
DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates
-
Ponti M, Souhami RL, Fox BW, et al. DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates. Br J Cancer 1991;63:743-747.
-
(1991)
Br J Cancer
, vol.63
, pp. 743-747
-
-
Ponti, M.1
Souhami, R.L.2
Fox, B.W.3
-
42
-
-
3042633821
-
DNA intrastrand cross-link at the 5'-GA- 3' sequence formed by busulfan and its role in the cytotoxic effect
-
Iwamoto T, Hiraku Y, Oikawa S, et al. DNA intrastrand cross-link at the 5'-GA- 3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci 2004;95:454-458.
-
(2004)
Cancer Sci
, vol.95
, pp. 454-458
-
-
Iwamoto, T.1
Hiraku, Y.2
Oikawa, S.3
-
43
-
-
41549130929
-
Newer cytotoxic agents: attacking cancer broadly
-
Teicher B. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;24:1610-1617.
-
(2008)
Clin Cancer Res
, vol.24
, pp. 1610-1617
-
-
Teicher, B.1
-
44
-
-
10644245994
-
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
-
Chaney SG, Campbell SL, Bassett E, et al. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3-11.
-
(2005)
Crit Rev Oncol Hematol
, vol.53
, pp. 3-11
-
-
Chaney, S.G.1
Campbell, S.L.2
Bassett, E.3
-
45
-
-
0031864830
-
Oxaliplatin: mechanism of action and antineoplastic activity
-
Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(Suppl 5):4-12.
-
(1998)
Semin Oncol
, vol.25
, pp. 4-12
-
-
Raymond, E.1
Faivre, S.2
Woynarowski, J.M.3
-
46
-
-
49249083377
-
Amifostine protects against cisplatin-induced ototoxicity in children with average risk medulloblastoma
-
Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average risk medulloblastoma. J Clin Oncol 2008;26:3749-3755.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3749-3755
-
-
Fouladi, M.1
Chintagumpala, M.2
Ashley, D.3
-
47
-
-
34547100275
-
The resurgence of platinum-based cancer chemotherapy
-
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev 2007;7:573-584.
-
(2007)
Nat Rev
, vol.7
, pp. 573-584
-
-
Kelland, L.1
-
48
-
-
0036288984
-
The cellular pharmacology of oxaliplatin resistance
-
Mishima M, Samimi G, Kondo A, et al. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002;38:1405-1412.
-
(2002)
Eur J Cancer
, vol.38
, pp. 1405-1412
-
-
Mishima, M.1
Samimi, G.2
Kondo, A.3
-
49
-
-
5344266052
-
Protein interactions with platinum- DNA adducts: from structure to function
-
Chaney SG, Campbell SL, Temple B, et al. Protein interactions with platinum- DNA adducts: from structure to function. J Inorg Biochem 2004;98:1551-1559.
-
(2004)
J Inorg Biochem
, vol.98
, pp. 1551-1559
-
-
Chaney, S.G.1
Campbell, S.L.2
Temple, B.3
-
50
-
-
3042782623
-
Cisplatin and related anticancer drugs: recent advances and insights
-
Barnes KR, Lippard SJ. Cisplatin and related anticancer drugs: recent advances and insights. Met Ions Biol Syst 2004;42:143-177.
-
(2004)
Met Ions Biol Syst
, vol.42
, pp. 143-177
-
-
Barnes, K.R.1
Lippard, S.J.2
-
51
-
-
23644432241
-
New-generation platinum drugs in the treatment of cisplatinresistant cancers
-
McKeage MJ. New-generation platinum drugs in the treatment of cisplatinresistant cancers. Expert Opin Invest Drugs 2005;14:1033-1046.
-
(2005)
Expert Opin Invest Drugs
, vol.14
, pp. 1033-1046
-
-
McKeage, M.J.1
-
52
-
-
17444422174
-
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
-
Kweekel DM, Gelderblom H, Guchelaar H-J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105.
-
(2005)
Cancer Treat Rev
, vol.31
, pp. 90-105
-
-
Kweekel, D.M.1
Gelderblom, H.2
Guchelaar, H.-J.3
-
53
-
-
0035003714
-
A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltagegated sodium channels
-
Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltagegated sodium channels. J Neurophysiol 2001;85:2293-2297.
-
(2001)
J Neurophysiol
, vol.85
, pp. 2293-2297
-
-
Grolleau, F.1
Gamelin, L.2
Boisdron-Celle, M.3
-
54
-
-
3042523914
-
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
-
Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-4061.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4055-4061
-
-
Gamelin, L.1
Boisdron-Celle, M.2
Delva, R.3
-
55
-
-
34447525351
-
Broadening the clinical use of platinum drug-based chemotherapy with new analogs: satraplatin and picoplatin
-
Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogs: satraplatin and picoplatin. Expert Opin Invest Drugs 2007;16:1009-1021.
-
(2007)
Expert Opin Invest Drugs
, vol.16
, pp. 1009-1021
-
-
Kelland, L.1
-
56
-
-
41549164880
-
Current status and future prospects for satraplatin, an oral platinum analog
-
Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analog. Clin Cancer Res 2008;14:1633-1638.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1633-1638
-
-
Choy, H.1
Park, C.2
Yao, M.3
-
57
-
-
77954187741
-
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs
-
Pommier Y, Leo E, Zhang HL, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol Rev 2010;17:421-433.
-
(2010)
Chem Biol Rev
, vol.17
, pp. 421-433
-
-
Pommier, Y.1
Leo, E.2
Zhang, H.L.3
-
58
-
-
35748968504
-
DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation
-
Dal Ben D, Palumbo M, Zagotto G, et al. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation. Curr Pharm Des 2007;13:2766-2780.
-
(2007)
Curr Pharm Des
, vol.13
, pp. 2766-2780
-
-
Dal Ben, D.1
Palumbo, M.2
Zagotto, G.3
-
59
-
-
0037180432
-
The mechanism of topoisomerase I poisoning by a camptothecin analog
-
Staker BL, Hjerrild K, Feese MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci 2002;99:15387-15392.
-
(2002)
Proc Natl Acad Sci
, vol.99
, pp. 15387-15392
-
-
Staker, B.L.1
Hjerrild, K.2
Feese, M.D.3
-
60
-
-
77955180152
-
Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I-DNA complex
-
Giordano M, D'Annessa I, Coletta A, et al. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I-DNA complex. PLos One 2010;5:e10934.
-
(2010)
PLos One
, vol.5
, pp. e10934
-
-
Giordano, M.1
D'Annessa, I.2
Coletta, A.3
-
61
-
-
17144371295
-
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex
-
Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-2345.
-
(2005)
J Med Chem
, vol.48
, pp. 2336-2345
-
-
Staker, B.L.1
Feese, M.D.2
Cushman, M.3
-
62
-
-
0002332484
-
Antineoplastic agents
-
In: Hardman JG, Limbird LE, eds. 10th ed. New York: McGraw Hill
-
Chabner BA, Ryan DP, Paz-Ares L, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw Hill, 2001:1389-1459.
-
(2001)
Goodman & Gilman's The Pharmacological Basis of Therapeutics
, pp. 1389-1459
-
-
Chabner, B.A.1
Ryan, D.P.2
Paz-Ares, L.3
-
63
-
-
33244477127
-
Topoisomerase interactive agents
-
In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. 7th ed. Baltimore: Lippincott Williams & Wilkins
-
Takimoto CH. Topoisomerase interactive agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Baltimore: Lippincott Williams & Wilkins, 2005:375-390.
-
(2005)
Cancer: Principles and Practice of Oncology
, pp. 375-390
-
-
Takimoto, C.H.1
-
64
-
-
72949121914
-
A comeback for camptothecins
-
Kirschbaum M. A comeback for camptothecins? Leuk Lymph 2009;50:1914-1915.
-
(2009)
Leuk Lymph
, vol.50
, pp. 1914-1915
-
-
Kirschbaum, M.1
-
65
-
-
71349085110
-
Quantitative structure-property relationships of camptothecins in humans
-
Xu C, Barchet TM, Mager DE. Quantitative structure-property relationships of camptothecins in humans. Cancer Chemother Pharmacol 2009;65:325-333.
-
(2009)
Cancer Chemother Pharmacol
, vol.65
, pp. 325-333
-
-
Xu, C.1
Barchet, T.M.2
Mager, D.E.3
-
66
-
-
77950588535
-
Cancer therapies using the camptothecins A review of the in vivo literature
-
Venditto VJ, Simanek EE. Cancer therapies using the camptothecins. A review of the in vivo literature. Mol Pharmacol 2010;7:307-349.
-
(2010)
Mol Pharmacol
, vol.7
, pp. 307-349
-
-
Venditto, V.J.1
Simanek, E.E.2
-
67
-
-
84855318100
-
Pharmacogenetics of irinotecan An ethnicity based prediction of irinotecan adverse effects
-
Shimoyama S. Pharmacogenetics of irinotecan. An ethnicity based prediction of irinotecan adverse effects. World J Gastrointest Surg 2010;2:14-21.
-
(2010)
World J Gastrointest Surg
, vol.2
, pp. 14-21
-
-
Shimoyama, S.1
-
68
-
-
65349181626
-
UGT1A16 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
-
Onoue M, Terada T, Kobayashi M, et al. UGT1A16 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009;14:136-142.
-
(2009)
Int J Clin Oncol
, vol.14
, pp. 136-142
-
-
Onoue, M.1
Terada, T.2
Kobayashi, M.3
-
69
-
-
70849083959
-
Development of a highly stable and targetable nanoliposomal formulation of topotecan
-
Drummond DC, Noble CO, Guo Z, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 2010;141:13-21.
-
(2010)
J Control Release
, vol.141
, pp. 13-21
-
-
Drummond, D.C.1
Noble, C.O.2
Guo, Z.3
-
70
-
-
0141940254
-
Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha
-
Vilain N, Tsai-Pflugfelder M, Benoit A, et al. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha. Nucleic Acids Res 2003;31:5714-5722.
-
(2003)
Nucleic Acids Res
, vol.31
, pp. 5714-5722
-
-
Vilain, N.1
Tsai-Pflugfelder, M.2
Benoit, A.3
-
71
-
-
76449107191
-
A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II
-
Chee GL, Yalowich JC, Bodner A, et al. A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. Bioorg Med Chem 2010;18:830-838.
-
(2010)
Bioorg Med Chem
, vol.18
, pp. 830-838
-
-
Chee, G.L.1
Yalowich, J.C.2
Bodner, A.3
-
72
-
-
78650517282
-
The binding modes and binding affinities of epipodophyllotoxin derivatives with human topoisomerase IIa
-
Naik PK, Dubey A, Soni K, et al. The binding modes and binding affinities of epipodophyllotoxin derivatives with human topoisomerase IIa. J. Molec Graph Model 2010;29:546-564.
-
(2010)
J. Molec Graph Model
, vol.29
, pp. 546-564
-
-
Naik, P.K.1
Dubey, A.2
Soni, K.3
-
73
-
-
0032189081
-
Secondary leukemias induced by topoisomerase-targeted drugs
-
Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-255.
-
(1998)
Biochim Biophys Acta
, vol.1400
, pp. 233-255
-
-
Felix, C.A.1
-
75
-
-
0033006172
-
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin
-
Gerwirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
-
(1999)
Biochem Pharmacol
, vol.57
, pp. 727-741
-
-
Gerwirtz, D.A.1
-
76
-
-
0035871958
-
Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs
-
Zunino F, Pratesi G, Perego P. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 2001;61:933-938.
-
(2001)
Biochem Pharmacol
, vol.61
, pp. 933-938
-
-
Zunino, F.1
Pratesi, G.2
Perego, P.3
-
77
-
-
6344226473
-
Interactions of novel morpholine and hexamethylene derivatives of anthracycline antibiotics with DNA
-
Piestrzeniecwicz MK, Wilmanska D, Szemraj J, et al. Interactions of novel morpholine and hexamethylene derivatives of anthracycline antibiotics with DNA. Z Naturforsch 2004;59:739-748.
-
(2004)
Z Naturforsch
, vol.59
, pp. 739-748
-
-
Piestrzeniecwicz, M.K.1
Wilmanska, D.2
Szemraj, J.3
-
78
-
-
41849106072
-
Cellular mechanisms of resistance against taxanes and anthracyclines in cancer: intrinsic and acquired
-
Chien AJ, Moasser MM. Cellular mechanisms of resistance against taxanes and anthracyclines in cancer: intrinsic and acquired. Semin Oncol 2008;35(Suppl 2):S1-S14.
-
(2008)
Semin Oncol
, vol.35
, pp. S1-S14
-
-
Chien, A.J.1
Moasser, M.M.2
-
79
-
-
5644297293
-
Reversal of cancer by green tea polyphenols
-
Mei Y, Qian F, Wei M, et al. Reversal of cancer by green tea polyphenols. J Pharm Pharmacol 2004;56:1307-1314.
-
(2004)
J Pharm Pharmacol
, vol.56
, pp. 1307-1314
-
-
Mei, Y.1
Qian, F.2
Wei, M.3
-
80
-
-
0034599915
-
Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance
-
Sadzuka Y, Sugiyama T, Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 2000;114:155-162.
-
(2000)
Toxicol Lett
, vol.114
, pp. 155-162
-
-
Sadzuka, Y.1
Sugiyama, T.2
Sonobe, T.3
-
81
-
-
0030889051
-
Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug resistant cell lines
-
Stammler G, Volm M. Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug resistant cell lines. Anticancer Drugs 1997;8:265-268.
-
(1997)
Anticancer Drugs
, vol.8
, pp. 265-268
-
-
Stammler, G.1
Volm, M.2
-
82
-
-
1642576976
-
Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agents
-
Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agents. Mol Pharmacol 2004;65:181-195.
-
(2004)
Mol Pharmacol
, vol.65
, pp. 181-195
-
-
Kwok, J.C.1
Richardson, D.R.2
-
83
-
-
67650233909
-
New developments in anthracycline- induced cardiotoxicity
-
Mordente A, Meucci E, Silvestrini GE, et al. New developments in anthracycline- induced cardiotoxicity. Curr Med Chem 2009;16:1656-1672.
-
(2009)
Curr Med Chem
, vol.16
, pp. 1656-1672
-
-
Mordente, A.1
Meucci, E.2
Silvestrini, G.E.3
-
84
-
-
0035190606
-
Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road
-
Lothstein L, Israel M, Sweatman TW. Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road. Drug Res Updates 2001;4:169-177.
-
(2001)
Drug Res Updates
, vol.4
, pp. 169-177
-
-
Lothstein, L.1
Israel, M.2
Sweatman, T.W.3
-
85
-
-
0742269397
-
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
-
Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130:1-7.
-
(2004)
J Cancer Res Clin Oncol
, vol.130
, pp. 1-7
-
-
Swain, S.M.1
Vici, P.2
-
86
-
-
1842559586
-
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
-
Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004;18:664-675.
-
(2004)
FASEB J
, vol.18
, pp. 664-675
-
-
Fogli, S.1
Nieri, P.2
Breschi, M.C.3
-
87
-
-
52949118777
-
Carbonyl reductase 1 is a predominant doxorubicin reductase in human liver
-
Kassner N, Huse K, Martin HJ, et al. Carbonyl reductase 1 is a predominant doxorubicin reductase in human liver. Drug Metab Dispos 2008;36:2113-2120.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 2113-2120
-
-
Kassner, N.1
Huse, K.2
Martin, H.J.3
-
88
-
-
42049114942
-
Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes
-
Yamashita T, Fukushima T, Ueda T. Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes. Leuk Lymph 2008;49:809-814.
-
(2008)
Leuk Lymph
, vol.49
, pp. 809-814
-
-
Yamashita, T.1
Fukushima, T.2
Ueda, T.3
-
89
-
-
39049089593
-
The use of dexrazoxane for the prevention of anthracycline extravasation injury
-
Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Invest Drugs 2008;17:217-223.
-
(2008)
Expert Opin Invest Drugs
, vol.17
, pp. 217-223
-
-
Hasinoff, B.B.1
-
90
-
-
74049111479
-
Predicting anthracycline benefit: have we made any progress
-
Moretti E, Oakman C, Di Leo A. Predicting anthracycline benefit: have we made any progress? Curr Opin Oncol 2009;21:507-515.
-
(2009)
Curr Opin Oncol
, vol.21
, pp. 507-515
-
-
Moretti, E.1
Oakman, C.2
Di Leo, A.3
-
91
-
-
0035164058
-
A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles
-
Waterhouse DN, Tardi PG, Mayer LD, et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001;24:903-920.
-
(2001)
Drug Saf
, vol.24
, pp. 903-920
-
-
Waterhouse, D.N.1
Tardi, P.G.2
Mayer, L.D.3
-
92
-
-
69249111858
-
Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle invasive bladder cancer
-
Grossman HB, O'Donnell MA, Cookson MS, et al. Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle invasive bladder cancer. Rev Urol 2008;10:281-289.
-
(2008)
Rev Urol
, vol.10
, pp. 281-289
-
-
Grossman, H.B.1
O'Donnell, M.A.2
Cookson, M.S.3
-
93
-
-
0037291073
-
Caffeine enhances the myocardial uptake of idarubicin but reverses its negative inotropic effect
-
Kang W, Weiss M. Caffeine enhances the myocardial uptake of idarubicin but reverses its negative inotropic effect. Naunyn Schmiedelbergs Arch Pharmacol 2003;367:151-155.
-
(2003)
Naunyn Schmiedelbergs Arch Pharmacol
, vol.367
, pp. 151-155
-
-
Kang, W.1
Weiss, M.2
-
94
-
-
17044391471
-
Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta
-
Correale J, Rush C, Amengual A, et al. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. J Neuroimmunol 2005;162:173-183.
-
(2005)
J Neuroimmunol
, vol.162
, pp. 173-183
-
-
Correale, J.1
Rush, C.2
Amengual, A.3
-
95
-
-
68249084554
-
Novel molecular mechanism for actinomycin D activity as an oncogenic promoter G-quadruplex binder
-
Kang H-J, Park H-J. Novel molecular mechanism for actinomycin D activity as an oncogenic promoter G-quadruplex binder. Biochemistry 2009;48:7392-7398.
-
(2009)
Biochemistry
, vol.48
, pp. 7392-7398
-
-
Kang, H.-J.1
Park, H.-J.2
-
96
-
-
12144287215
-
The immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy
-
Basu S, Brown JE, Flannigan GM, et al. The immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 2004;109:703-709.
-
(2004)
Int J Cancer
, vol.109
, pp. 703-709
-
-
Basu, S.1
Brown, J.E.2
Flannigan, G.M.3
-
97
-
-
0037373090
-
NAD(P)H:quinone oxidoreductase 1 expression in kidney podocytes
-
Zappa F, Ward T, Pedrinis E, et al. NAD(P)H:quinone oxidoreductase 1 expression in kidney podocytes. J Histochem Cytochem 2003;51:297-302.
-
(2003)
J Histochem Cytochem
, vol.51
, pp. 297-302
-
-
Zappa, F.1
Ward, T.2
Pedrinis, E.3
-
98
-
-
77953486102
-
Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs
-
Snodgrass RG, Collier AC, Coon AE, et al. Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs. J Biol Chem 2010;285:19068-19075.
-
(2010)
J Biol Chem
, vol.285
, pp. 19068-19075
-
-
Snodgrass, R.G.1
Collier, A.C.2
Coon, A.E.3
-
99
-
-
38949179532
-
Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential
-
Colucci MA, Moody CJ, Couch GD. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org Biomol Chem 2008;6:637-656.
-
(2008)
Org Biomol Chem
, vol.6
, pp. 637-656
-
-
Colucci, M.A.1
Moody, C.J.2
Couch, G.D.3
-
100
-
-
51649099040
-
Further insights into the mechanism of the reaction of activated bleomycin with DNA
-
Chow MS, Liu LV, Soloman EI. Further insights into the mechanism of the reaction of activated bleomycin with DNA. Proc Natl Acad Sci 2008;105:13241-13245.
-
(2008)
Proc Natl Acad Sci
, vol.105
, pp. 13241-13245
-
-
Chow, M.S.1
Liu, L.V.2
Soloman, E.I.3
-
101
-
-
0022000435
-
Origin and cytotoxic properties of base propenals derived from DNA
-
Grollman AP, Takeshita M, Pillai KMR, et al. Origin and cytotoxic properties of base propenals derived from DNA. Cancer Res 1985;45:1127-1131.
-
(1985)
Cancer Res
, vol.45
, pp. 1127-1131
-
-
Grollman, A.P.1
Takeshita, M.2
Pillai, K.M.R.3
-
102
-
-
8444244570
-
Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis
-
Brewer GJ, Dick R, Ullenbruch MR, et al. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98:2160-2167.
-
(2004)
J Inorg Biochem
, vol.98
, pp. 2160-2167
-
-
Brewer, G.J.1
Dick, R.2
Ullenbruch, M.R.3
-
103
-
-
77956524295
-
Angiotensin converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury
-
Li P, Xiao HD, Xu J, et al. Angiotensin converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol 2010;177:1113-1121.
-
(2010)
Am J Pathol
, vol.177
, pp. 1113-1121
-
-
Li, P.1
Xiao, H.D.2
Xu, J.3
-
104
-
-
0035988820
-
Macropodid herpesvirus 1 encodes genes for both thymidylate synthase and ICP34.5
-
Guliana S, Polkinghorne I, Smith GA, et al. Macropodid herpesvirus 1 encodes genes for both thymidylate synthase and ICP34.5. Virus Genes 2002;24:207-213.
-
(2002)
Virus Genes
, vol.24
, pp. 207-213
-
-
Guliana, S.1
Polkinghorne, I.2
Smith, G.A.3
-
105
-
-
0029619543
-
Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site
-
Schiffer CA, Clifton IJ, Davisson VJ, et al. Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. Biochemistry 1995;34:16279-16287.
-
(1995)
Biochemistry
, vol.34
, pp. 16279-16287
-
-
Schiffer, C.A.1
Clifton, I.J.2
Davisson, V.J.3
-
106
-
-
77953139949
-
Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase
-
Jarmula A, Fraczyk T, Cieplak P, et al. Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase. Bioorg Med Chem 2010;18:3361-3370.
-
(2010)
Bioorg Med Chem
, vol.18
, pp. 3361-3370
-
-
Jarmula, A.1
Fraczyk, T.2
Cieplak, P.3
-
107
-
-
0026794266
-
Structural basis for recognition of polyglutamyl folates by thymidylate synthase
-
Kamb A, Finer-Moore J, Calvert AH, et al. Structural basis for recognition of polyglutamyl folates by thymidylate synthase. Biochemistry 1992;31:9883-9890.
-
(1992)
Biochemistry
, vol.31
, pp. 9883-9890
-
-
Kamb, A.1
Finer-Moore, J.2
Calvert, A.H.3
-
108
-
-
33747169515
-
Dihydropyrimidine dehydrogenase defi- ciency: impact of pharmacogenetics on 5-fluorouracil therapy
-
Lee A, Ezzeldin H, Fourie J, et al. Dihydropyrimidine dehydrogenase defi- ciency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol 2004;2:527-532.
-
(2004)
Clin Adv Hematol Oncol
, vol.2
, pp. 527-532
-
-
Lee, A.1
Ezzeldin, H.2
Fourie, J.3
-
109
-
-
33749350447
-
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared to Caucasians
-
Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared to Caucasians. Cancer Ther Clin 2006;12:5491-5495.
-
(2006)
Cancer Ther Clin
, vol.12
, pp. 5491-5495
-
-
Mattison, L.K.1
Fourie, J.2
Desmond, R.A.3
-
110
-
-
33748501145
-
Antimetabolites
-
In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. 7th ed. Baltimore: Lippincott Williams & Wilkins
-
Kummar S, Noronha V, Chu E. Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Baltimore: Lippincott Williams & Wilkins, 2005:365-374.
-
(2005)
Cancer: Principles and Practice of Oncology
, pp. 365-374
-
-
Kummar, S.1
Noronha, V.2
Chu, E.3
-
111
-
-
84961978282
-
Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase
-
Dummins PL, Gready JE. Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase. J Am Chem Soc 2001;123:3418-3428.
-
(2001)
J Am Chem Soc
, vol.123
, pp. 3418-3428
-
-
Dummins, P.L.1
Gready, J.E.2
-
112
-
-
0027080589
-
Crystal structure determination at 2.3 angstrom of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-?-tetrazole
-
Cody V, Luft JR, Ciszak E, et al. Crystal structure determination at 2.3 angstrom of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-?-tetrazole. Anticancer Drug Des 1992;7:483-491.
-
(1992)
Anticancer Drug Des
, vol.7
, pp. 483-491
-
-
Cody, V.1
Luft, J.R.2
Ciszak, E.3
-
113
-
-
0030875357
-
Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate
-
Cannon WR, Garrison BJ, Benkovic SJ. Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate. J Mol Biol 1997;271:656-668.
-
(1997)
J Mol Biol
, vol.271
, pp. 656-668
-
-
Cannon, W.R.1
Garrison, B.J.2
Benkovic, S.J.3
-
114
-
-
0028924642
-
Contributions of tryptophan 24 and glutamate 30 to binding long-lived water molecules in the ternary complex of human dihydrofolate reductase with methotrexate and NADPH studies by site directed mutagenesis and nuclear magnetic resonance spectroscopy
-
Meiering EM, Li H, Delcamp TJ, et al. Contributions of tryptophan 24 and glutamate 30 to binding long-lived water molecules in the ternary complex of human dihydrofolate reductase with methotrexate and NADPH studies by site directed mutagenesis and nuclear magnetic resonance spectroscopy. J Mol Biol 1995;241:309-325.
-
(1995)
J Mol Biol
, vol.241
, pp. 309-325
-
-
Meiering, E.M.1
Li, H.2
Delcamp, T.J.3
-
116
-
-
77949435506
-
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
-
Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Topics 2010;11:37-47.
-
(2010)
Curr Drug Topics
, vol.11
, pp. 37-47
-
-
Joerger, M.1
Omlin, A.2
Cerny, T.3
-
117
-
-
33646338595
-
Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy
-
Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 2006;26:641-654.
-
(2006)
Pharmacotherapy
, vol.26
, pp. 641-654
-
-
Villela, L.R.1
Stanford, B.L.2
Shah, S.R.3
-
118
-
-
0032950347
-
Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis
-
Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26(Suppl 6):42-47.
-
(1999)
Semin Oncol
, vol.26
, pp. 42-47
-
-
Mendelsohn, L.G.1
Shih, C.2
Chen, V.J.3
-
119
-
-
0035798375
-
Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases
-
Sayre PH, Finer-Moore JS, Fritz TA, et al. Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases. J Mol Biol 2001;313:813-829.
-
(2001)
J Mol Biol
, vol.313
, pp. 813-829
-
-
Sayre, P.H.1
Finer-Moore, J.S.2
Fritz, T.A.3
-
120
-
-
0036673489
-
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantition of drug interactions in human HT29 colon cancer cells
-
Raymond E, Louvet C, Tournigand C, et al. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantition of drug interactions in human HT29 colon cancer cells. Int J Oncol 2002;21:361-367.
-
(2002)
Int J Oncol
, vol.21
, pp. 361-367
-
-
Raymond, E.1
Louvet, C.2
Tournigand, C.3
-
121
-
-
78049426102
-
ABCC11/MRP8 confers pemetrexed resistance in lung cancer
-
Uemura T, Oguri T, Ozasa H, et al. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci 2010;101:2404-2410.
-
(2010)
Cancer Sci
, vol.101
, pp. 2404-2410
-
-
Uemura, T.1
Oguri, T.2
Ozasa, H.3
-
122
-
-
0023521286
-
10-Ethyl-10-deaza-aminopterin: strucrtural design and biochemical, pharmacologic, and antitumor properties
-
Sirotnak FM, Schmid GA, Samuels LL, et al. 10-Ethyl-10-deaza-aminopterin: strucrtural design and biochemical, pharmacologic, and antitumor properties. Natl Cancer Inst Monogr 1987;5:127-131.
-
(1987)
Natl Cancer Inst Monogr
, vol.5
, pp. 127-131
-
-
Sirotnak, F.M.1
Schmid, G.A.2
Samuels, L.L.3
-
123
-
-
69049101976
-
Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
-
Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009;64:993-999.
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 993-999
-
-
Izbicka, E.1
Diaz, A.2
Streeper, R.3
-
124
-
-
34848829782
-
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractor cases of T-cell lymphoma
-
O'Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractor cases of T-cell lymphoma. Br J Haematol 2007;139:425-428.
-
(2007)
Br J Haematol
, vol.139
, pp. 425-428
-
-
O'Connor, O.A.1
Hamlin, P.A.2
Portlock, C.3
-
125
-
-
33748908563
-
Pralatreate: an emerging new agent with activity in T-cell lymphoma
-
O'Connor OA. Pralatreate: an emerging new agent with activity in T-cell lymphoma. Curr Opin Oncol 2006;18:591-597.
-
(2006)
Curr Opin Oncol
, vol.18
, pp. 591-597
-
-
O'Connor, O.A.1
-
126
-
-
46749119475
-
Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies
-
Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 2008;11:508-521.
-
(2008)
IDrugs
, vol.11
, pp. 508-521
-
-
Molina, J.R.1
-
127
-
-
67650240123
-
Pralatrexate, a new hope for aggressive T-cell lymphoma
-
Rueda A, Casanova M, Quero C, et al. Pralatrexate, a new hope for aggressive T-cell lymphoma? Clin Transl Oncol 2009;11:215-220.
-
(2009)
Clin Transl Oncol
, vol.11
, pp. 215-220
-
-
Rueda, A.1
Casanova, M.2
Quero, C.3
-
128
-
-
67651202352
-
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma
-
Mould DR, Sweeney K, Duffull SB, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2008;86:190-196.
-
(2008)
Clin Pharmacol Ther
, vol.86
, pp. 190-196
-
-
Mould, D.R.1
Sweeney, K.2
Duffull, S.B.3
-
129
-
-
78751474637
-
Single agent and combination studies of pralatexate and molecular correlates of sensitivity
-
Serova M, Bieche I, Sablin MP, et al. Single agent and combination studies of pralatexate and molecular correlates of sensitivity. Br J Cancer 2011;104:272-280.
-
(2011)
Br J Cancer
, vol.104
, pp. 272-280
-
-
Serova, M.1
Bieche, I.2
Sablin, M.P.3
-
130
-
-
0036082415
-
The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs
-
Coulthard SA, Hogarth LA, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharamcol 2002;62:102-109.
-
(2002)
Mol Pharamcol
, vol.62
, pp. 102-109
-
-
Coulthard, S.A.1
Hogarth, L.A.2
Little, M.3
-
131
-
-
9144252139
-
Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice
-
Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Mont 2004;10:247-254.
-
(2004)
Med Sci Mont
, vol.10
, pp. 247-254
-
-
Cara, C.J.1
Pena, A.S.2
Sans, M.3
-
132
-
-
58449111231
-
The increasing complexity of mercaptopurine pharmacogenomics
-
Marsh S, Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009;85:139-141.
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 139-141
-
-
Marsh, S.1
Booven, D.J.2
-
133
-
-
34250356290
-
Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics
-
Hartford C, Vasquez E, Schwab M, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007;67:4965-4972.
-
(2007)
Cancer Res
, vol.67
, pp. 4965-4972
-
-
Hartford, C.1
Vasquez, E.2
Schwab, M.3
-
134
-
-
58449117037
-
Genetic polymorphism of inositol triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for lymphoblastic leukemia
-
Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inositol triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for lymphoblastic leukemia. Clin Pharmacol Ther 2009;85:164-172.
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 164-172
-
-
Stocco, G.1
Cheok, M.H.2
Crews, K.R.3
-
136
-
-
33750435940
-
Impaired transport as a mechanism of resistance to thiopurines in human T-lymphoblastic leukemia cells
-
Fotoohi AK, Lindqvist M, Peterson C, et al. Impaired transport as a mechanism of resistance to thiopurines in human T-lymphoblastic leukemia cells. Nucleosides Nucleotides Nucleic Acids 2006;25:1039-1044.
-
(2006)
Nucleosides Nucleotides Nucleic Acids
, vol.25
, pp. 1039-1044
-
-
Fotoohi, A.K.1
Lindqvist, M.2
Peterson, C.3
-
137
-
-
42049091651
-
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells
-
Cai J, Damaraju VL, Grouix N, et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008;68:2349-2357.
-
(2008)
Cancer Res
, vol.68
, pp. 2349-2357
-
-
Cai, J.1
Damaraju, V.L.2
Grouix, N.3
-
138
-
-
70649100419
-
Genetic factors influencing cytarabine therapy
-
Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009;10:1657-1674.
-
(2009)
Pharmacogenomics
, vol.10
, pp. 1657-1674
-
-
Lamba, J.K.1
-
139
-
-
70349490598
-
Pentostatin treatment combinations in chronic lymphocytic leukemia
-
Lamanna N, Kay NE. Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009;7:386-392.
-
(2009)
Clin Adv Hematol Oncol
, vol.7
, pp. 386-392
-
-
Lamanna, N.1
Kay, N.E.2
-
140
-
-
78650177166
-
Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications
-
Kovacic P. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses 2011;76:24-31.
-
(2011)
Med Hypotheses
, vol.76
, pp. 24-31
-
-
Kovacic, P.1
-
141
-
-
33646271817
-
Novel tubulin-interacting agents: a tale of Taxus brevifolia and Cantharanthus roseus-based drug discovery
-
Chen S-H, Hong J. Novel tubulin-interacting agents: a tale of Taxus brevifolia and Cantharanthus roseus-based drug discovery. Drugs Future 2006;31:123-150.
-
(2006)
Drugs Future
, vol.31
, pp. 123-150
-
-
Chen, S.-H.1
Hong, J.2
-
142
-
-
77955080328
-
Microtubule-binding natural products for cancer therapy
-
Yue QX, Liu X, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med 2010;76:1037-1043.
-
(2010)
Planta Med
, vol.76
, pp. 1037-1043
-
-
Yue, Q.X.1
Liu, X.2
Guo, D.A.3
-
143
-
-
77954564134
-
Antimicrotubule agents
-
In: DeVita VT Jr, Lawrence TS, Hellman, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Lee JJ, Harris LN. Antimicrotubule agents. In: DeVita VT Jr, Lawrence TS, Hellman, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:447-456.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 447-456
-
-
Lee, J.J.1
Harris, L.N.2
-
144
-
-
50249139544
-
The individualization of cancer therapy: the unexpected role of p53
-
Hait WN, Yang J-M. The individualization of cancer therapy: the unexpected role of p53. Transact Am Clin Climatol Assoc 2006;117:85-101.
-
(2006)
Transact Am Clin Climatol Assoc
, vol.117
, pp. 85-101
-
-
Hait, W.N.1
Yang, J.-M.2
-
145
-
-
0141455184
-
3D QSAR studies for the ß-tubulin binding site of microtubule-stabilizing anticancer agents (MSAAs) A pseudoreceptor model for taxanes based on the experimental structure of tubulin
-
Maccari L, Manetti F, Corelli, F, et al. 3D QSAR studies for the ß-tubulin binding site of microtubule-stabilizing anticancer agents (MSAAs). A pseudoreceptor model for taxanes based on the experimental structure of tubulin. Il Farmaco 2003;58:659-668.
-
(2003)
Il Farmaco
, vol.58
, pp. 659-668
-
-
Maccari, L.1
Manetti, F.2
Corelli, F.3
-
146
-
-
0034850721
-
General and recent aspects of the chemistry and structure-activity relationships of taxoids
-
Gueritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Des 2001;7:1229-1249.
-
(2001)
Curr Pharm Des
, vol.7
, pp. 1229-1249
-
-
Gueritte, F.1
-
147
-
-
0037212671
-
Investigation of structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA
-
Islam MN, Song Y, Iskander MN. Investigation of structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA. J Mol Graph Model 2003;21:263-272.
-
(2003)
J Mol Graph Model
, vol.21
, pp. 263-272
-
-
Islam, M.N.1
Song, Y.2
Iskander, M.N.3
-
148
-
-
0037407830
-
3D QSAR studies of the interaction between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA) A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones
-
Manetti F, Forli S, Maccari L, et al. 3D QSAR studies of the interaction between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones. Il Farmaco 2003;58:357-361.
-
(2003)
Il Farmaco
, vol.58
, pp. 357-361
-
-
Manetti, F.1
Forli, S.2
Maccari, L.3
-
149
-
-
1542394399
-
3D QSAR models of interactions between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones
-
Manetti F, Maccari L, Corelli F, et al. 3D QSAR models of interactions between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones. Curr Topics Med Chem 2004;4:203-217.
-
(2004)
Curr Topics Med Chem
, vol.4
, pp. 203-217
-
-
Manetti, F.1
Maccari, L.2
Corelli, F.3
-
150
-
-
65249112145
-
The tubulin-bound conformation of paclitaxel: T-taxol vs
-
Yang Y, Alcaraz AA, Snyder JP. The tubulin-bound conformation of paclitaxel: T-taxol vs. "PTX-NY." J Natl Prod 2009;72:422-429.
-
(2009)
"PTX-NY." J Natl Prod
, vol.72
, pp. 422-429
-
-
Yang, Y.1
Alcaraz, A.A.2
Snyder, J.P.3
-
151
-
-
2442719015
-
Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs and minipigs
-
Vaclavikova R, Soucek P, Svobodova L, et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs and minipigs. Drug Metab Dispos 2004;32:666-674.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 666-674
-
-
Vaclavikova, R.1
Soucek, P.2
Svobodova, L.3
-
152
-
-
0141993644
-
Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants
-
Vaclavikova R, Horsky S, Simek P, et al. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn- Schmiedelbergs Arch Pharmacol 2003;368:200-209.
-
(2003)
Naunyn- Schmiedelbergs Arch Pharmacol
, vol.368
, pp. 200-209
-
-
Vaclavikova, R.1
Horsky, S.2
Simek, P.3
-
153
-
-
0036201599
-
Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship
-
Cresteil T, Monsarrat B, DuBois J, et al. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;39:438-445.
-
(2002)
Drug Metab Dispos
, vol.39
, pp. 438-445
-
-
Cresteil, T.1
Monsarrat, B.2
DuBois, J.3
-
154
-
-
0002332484
-
Antineoplastic agents
-
In: Hardman JG, Limbird LE, eds. 10th ed. New York: McGraw Hill
-
Chabner BA, Ryan DP, Paz-Ares L, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw Hill, 2001:1389-1459.
-
(2001)
Goodman & Gilman's The Pharmacological Basis of Therapeutics
, pp. 1389-1459
-
-
Chabner, B.A.1
Ryan, D.P.2
Paz-Ares, L.3
-
155
-
-
1542380040
-
Interation of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity
-
Buey RM, Diaz JF, Andreu JM, et al. Interation of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol 2004;11:225-236.
-
(2004)
Chem Biol
, vol.11
, pp. 225-236
-
-
Buey, R.M.1
Diaz, J.F.2
Andreu, J.M.3
-
156
-
-
0038349992
-
Epothilone B and its analogs: a new family of anticancer agents
-
Altmann K-H. Epothilone B and its analogs: a new family of anticancer agents. Mini Rev Med Chem 2003;3:149-158.
-
(2003)
Mini Rev Med Chem
, vol.3
, pp. 149-158
-
-
Altmann, K.-H.1
-
157
-
-
60849093178
-
Discovery of ixabepilone
-
Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009;8:275-281.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 275-281
-
-
Hunt, J.T.1
-
158
-
-
14844338576
-
Much anticipated-the bioactive conformation of epothilone and its binding to tubulin
-
Heinz DW, Schubert W-D, Hofle G. Much anticipated-the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed 2005;44:1298-1301.
-
(2005)
Angew Chem Int Ed
, vol.44
, pp. 1298-1301
-
-
Heinz, D.W.1
Schubert, W.-D.2
Hofle, G.3
-
159
-
-
4444338900
-
Tubulin-targeting agents
-
In: Giaconne G, Schilsky R, Sondel P, eds. New York: Elsevier B.V.
-
Hait WN, Rubin E, Goodin S. Tubulin-targeting agents. In: Giaconne G, Schilsky R, Sondel P, eds. Cancer Chemotherapy and Biological Response Modifiers. New York: Elsevier B.V., 2003:41-67.
-
(2003)
Cancer Chemotherapy and Biological Response Modifiers.
, pp. 41-67
-
-
Hait, W.N.1
Rubin, E.2
Goodin, S.3
-
160
-
-
2042474777
-
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
-
Engles FK, Ten-Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004;75:448-454.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 448-454
-
-
Engles, F.K.1
Ten-Tije, A.J.2
Baker, S.D.3
-
161
-
-
59449102526
-
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
-
Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-730.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 723-730
-
-
Mita, A.C.1
Denis, L.J.2
Rowinsky, E.K.3
-
162
-
-
50849088935
-
A multicenter phase II study of XRP2658 administered as a 1-hr i.v infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
-
Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP2658 administered as a 1-hr i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-1552.
-
(2008)
Ann Oncol
, vol.19
, pp. 1547-1552
-
-
Pivot, X.1
Koralewski, P.2
Hidalgo, J.L.3
-
163
-
-
77953163579
-
XRP6258-induced gene expression patterns in head and neck cancer carcinomas
-
Yoo GH, Kafri Z, Ensley JF, et al. XRP6258-induced gene expression patterns in head and neck cancer carcinomas. Laryngoscope 2010;120:1114-1119.
-
(2010)
Laryngoscope
, vol.120
, pp. 1114-1119
-
-
Yoo, G.H.1
Kafri, Z.2
Ensley, J.F.3
-
164
-
-
45549107529
-
Epothilones: clinical update and future directions
-
Donovan D, Vahdat LT. Epothilones: clinical update and future directions. Oncology 2008;22:408-416.
-
(2008)
Oncology
, vol.22
, pp. 408-416
-
-
Donovan, D.1
Vahdat, L.T.2
-
165
-
-
20044379059
-
Review: tubulin function, actions of antitubulin drugs, and new drug development
-
Pellegrini F, Budman DR. Review: tubulin function, actions of antitubulin drugs, and new drug development. Cancer Invest 2005;23:264-273.
-
(2005)
Cancer Invest
, vol.23
, pp. 264-273
-
-
Pellegrini, F.1
Budman, D.R.2
-
166
-
-
19544393159
-
Structual basis for the regulation of tubulin by vinblastine
-
Gigant B, Wang C, Ravelli RBG, et al. Structual basis for the regulation of tubulin by vinblastine. Nature 2005;435:519-522.
-
(2005)
Nature
, vol.435
, pp. 519-522
-
-
Gigant, B.1
Wang, C.2
Ravelli, R.B.G.3
-
167
-
-
0011823211
-
Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes and epothiolones
-
In: Bast RC Jr, Kufe DW, Pollock RE, et al., eds. 5th ed. New York: BC Decker Inc.
-
Beck WT, Cass CE, Houghton PJ. Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes and epothiolones. In: Bast RC Jr, Kufe DW, Pollock RE, et al., eds. Cancer Medicine, 5th ed. New York: BC Decker Inc., 2003:680-698.
-
(2003)
Cancer Medicine
, pp. 680-698
-
-
Beck, W.T.1
Cass, C.E.2
Houghton, P.J.3
-
168
-
-
9144254574
-
Microtubulin binding sites as target for developing anticancer agents
-
Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4:1077-1104.
-
(2004)
Mini Rev Med Chem
, vol.4
, pp. 1077-1104
-
-
Islam, M.N.1
Iskander, M.N.2
-
169
-
-
0026327465
-
Interactions of the catharanthus (vinca) alkaloids with tubulin and microtubules
-
Himes RH. Interactions of the catharanthus (vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 1991;51:257-267.
-
(1991)
Pharmacol Ther
, vol.51
, pp. 257-267
-
-
Himes, R.H.1
-
170
-
-
78651110078
-
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia
-
Egbelakin A, Ferguson MJ, MacGill EA. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;56:361-367.
-
(2011)
Pediatr Blood Cancer
, vol.56
, pp. 361-367
-
-
Egbelakin, A.1
Ferguson, M.J.2
MacGill, E.A.3
-
171
-
-
4644273573
-
Severe bone marrow depression induced by the anticancer herb Cantharanthus roseus
-
Wu ML, Deng JF, Wu JC, et al. Severe bone marrow depression induced by the anticancer herb Cantharanthus roseus. J Toxicol Clin Toxicol 2005;43:667-671.
-
(2005)
J Toxicol Clin Toxicol
, vol.43
, pp. 667-671
-
-
Wu, M.L.1
Deng, J.F.2
Wu, J.C.3
-
172
-
-
33645624425
-
Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine
-
Beulz-Riche D, Grude P, Puozzo C, et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 2005;19:545-553.
-
(2005)
Fundam Clin Pharmacol
, vol.19
, pp. 545-553
-
-
Beulz-Riche, D.1
Grude, P.2
Puozzo, C.3
-
173
-
-
0033840446
-
CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes
-
Jakita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000;28:1121-1127.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 1121-1127
-
-
Jakita, J.1
Kuwabara, T.2
Kobayashi, H.3
-
174
-
-
0031039994
-
Interaction of estramustine with tubulin isotypes
-
Laing N, Dahllof B, Hartley-Asp B, et al. Interaction of estramustine with tubulin isotypes. Biochemistry 1997;36:871-878.
-
(1997)
Biochemistry
, vol.36
, pp. 871-878
-
-
Laing, N.1
Dahllof, B.2
Hartley-Asp, B.3
-
175
-
-
67649726156
-
Protein kinase inhibitors: contributions from structure to clinical compounds
-
Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Quart Rev Biophys 2009;42:1-40.
-
(2009)
Quart Rev Biophys
, vol.42
, pp. 1-40
-
-
Johnson, L.N.1
-
176
-
-
18744394349
-
Strategies for the design of potent and selective kinase inhibitors
-
McInnes C, Fisher PM. Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Des 2005;11:1845-1863.
-
(2005)
Curr Pharm Des
, vol.11
, pp. 1845-1863
-
-
McInnes, C.1
Fisher, P.M.2
-
177
-
-
77649204688
-
Selectively nonselective kinase inhibition: striking the right balance
-
Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 2010;53:1413-1437.
-
(2010)
J Med Chem
, vol.53
, pp. 1413-1437
-
-
Morphy, R.1
-
178
-
-
61549138378
-
Imatinib and its successors: how modern chemistry has changed drug development
-
Muller BA. Imatinib and its successors: how modern chemistry has changed drug development. Curr Pharm Des 2009;15:120-133.
-
(2009)
Curr Pharm Des
, vol.15
, pp. 120-133
-
-
Muller, B.A.1
-
179
-
-
0041466445
-
Specific targeted therapy of chronic myelogenous leukemia with imatinib
-
Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-422.
-
(2003)
Pharmacol Rev
, vol.55
, pp. 401-422
-
-
Deininger, M.W.N.1
Druker, B.J.2
-
180
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
181
-
-
77957903356
-
New insights into small-molecule inhibitors of Bcr-Abl
-
Schenone S, Bruno O, Radi M, et al. New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev 2009;31:1-41.
-
(2009)
Med Res Rev
, vol.31
, pp. 1-41
-
-
Schenone, S.1
Bruno, O.2
Radi, M.3
-
182
-
-
55549093089
-
Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia
-
Jarkowski A III, Sweeny RP. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Pharmacotherapy 2008;28:1374-1382.
-
(2008)
Pharmacotherapy
, vol.28
, pp. 1374-1382
-
-
Jarkowski, A.1
Sweeny, R.P.2
-
183
-
-
33745283618
-
The structure of dasatinib (BMS- 354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants
-
Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS- 354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants. Cancer Res 2006;66:5790-5797.
-
(2006)
Cancer Res
, vol.66
, pp. 5790-5797
-
-
Tokarski, J.S.1
Newitt, J.A.2
Chang, C.Y.J.3
-
184
-
-
0028142387
-
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
-
Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1095.
-
(1994)
Science
, vol.265
, pp. 1093-1095
-
-
Fry, D.W.1
Kraker, A.J.2
McMichael, A.3
-
185
-
-
0033061032
-
Protein tyrosine kinase inhibitors as novel therapeutic agents
-
Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 1999;82:231-239.
-
(1999)
Pharmacol Ther
, vol.82
, pp. 231-239
-
-
Levitzki, A.1
-
186
-
-
41649099467
-
Structural insights on how irreversible inhibitors can overcome drug resistance in EGFR
-
Michalczyk A, Kluter S, Rode HB, et al. Structural insights on how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem 2008;16:3482-3488.
-
(2008)
Bioorg Med Chem
, vol.16
, pp. 3482-3488
-
-
Michalczyk, A.1
Kluter, S.2
Rode, H.B.3
-
187
-
-
77951983285
-
Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode
-
Kettle JG, Ward RA. Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode. J Chem Inf Model 2010;50:525-533.
-
(2010)
J Chem Inf Model
, vol.50
, pp. 525-533
-
-
Kettle, J.G.1
Ward, R.A.2
-
188
-
-
36749034794
-
Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, kit, plateletderived growth factor receptor, ras
-
Erman M. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, kit, plateletderived growth factor receptor, ras. J BUON 2007;12(Suppl 1):S83-S94.
-
(2007)
J BUON
, vol.12
, pp. S83-S94
-
-
Erman, M.1
-
189
-
-
0030945871
-
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
-
Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997;276:955-960.
-
(1997)
Science
, vol.276
, pp. 955-960
-
-
Mohammadi, M.1
McMahon, G.2
Sun, L.3
-
190
-
-
78751559152
-
Small-molecule tyrosine kinase inhibitors
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
LoRusso PM, Ryan AJ, Boerner SA, et al. Small-molecule tyrosine kinase inhibitors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:457-468.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 457-468
-
-
LoRusso, P.M.1
Ryan, A.J.2
Boerner, S.A.3
-
191
-
-
77956868186
-
Metabolism considerations for kinase inhibitors in cancer treatment
-
Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin 2010;6:1775-1193.
-
(2010)
Expert Opin
, vol.6
, pp. 1775-1193
-
-
Duckett, D.R.1
Cameron, M.D.2
-
192
-
-
70349669267
-
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters
-
Chen HS, Franke R, Orwick S, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062-6069.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 6062-6069
-
-
Chen, H.S.1
Franke, R.2
Orwick, S.3
-
194
-
-
34547459725
-
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer
-
Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144.
-
(2007)
Pharmacotherapy
, vol.27
, pp. 1125-1144
-
-
Grandinetti, C.A.1
Goldspiel, B.R.2
-
195
-
-
38949140475
-
Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma protein expression
-
Vinodhkumar R, Song YS, Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma protein expression. Biomed Pharmacother 2008;62:85-93.
-
(2008)
Biomed Pharmacother
, vol.62
, pp. 85-93
-
-
Vinodhkumar, R.1
Song, Y.S.2
Devaki, T.3
-
196
-
-
84895290964
-
Histone deacetylase inhibitors and demethylating agents
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Gore SD, Baylin SB, Herman JG. Histone deacetylase inhibitors and demethylating agents. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:477-485.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 477-485
-
-
Gore, S.D.1
Baylin, S.B.2
Herman, J.G.3
-
197
-
-
49849103540
-
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
-
Newbold A, Lindemann RK, Cluse LA, et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008;7:1066-1079.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1066-1079
-
-
Newbold, A.1
Lindemann, R.K.2
Cluse, L.A.3
-
198
-
-
77954879663
-
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma
-
Whittaker SJ, Demierre M-F, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-4491.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4485-4491
-
-
Whittaker, S.J.1
Demierre, M.-F.2
Kim, E.J.3
-
199
-
-
33750306385
-
Stability studies of vorinostat and its two metabolites in human plasma, serum, and urine
-
Du L, Musson DG, Wang AQ, Stability studies of vorinostat and its two metabolites in human plasma, serum, and urine. J Pharm Biomed Anal 2006;42:556-564.
-
(2006)
J Pharm Biomed Anal
, vol.42
, pp. 556-564
-
-
Du, L.1
Musson, D.G.2
Wang, A.Q3
-
200
-
-
84971318543
-
-
Accessed January
-
Zolinza. http://www.zolinza.com/vorinostat/zolinza/consumer/about/actprogram. jsp. Accessed January 9, 2011.
-
(2011)
, vol.9
-
-
-
201
-
-
36048953657
-
Phocomelia and internal defects due to thalidomide
-
Lecutier MA. Phocomelia and internal defects due to thalidomide. Br Med J 1962;2:1147-1147.
-
(1962)
Br Med J
, vol.2
, pp. 1147-1147
-
-
Lecutier, M.A.1
-
202
-
-
0001960621
-
Miscellaneous chemotherapeutic agents
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Copur MS, Rose M, Gettinger SN. Miscellaneous chemotherapeutic agents. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:490-495.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 490-495
-
-
Copur, M.S.1
Rose, M.2
Gettinger, S.N.3
-
203
-
-
0031580639
-
Thalidomide ban to be lifted in the US
-
Rutter T. Thalidomide ban to be lifted in the US. Br Med J 1997;315:699.
-
(1997)
Br Med J
, vol.315
, pp. 699
-
-
Rutter, T.1
-
204
-
-
0041412631
-
Thalidomide: from teratogen to antiangiogenic
-
Grover JK, Vats K. Thalidomide: from teratogen to antiangiogenic. Indian J Cancer 2001;38:22-32.
-
(2001)
Indian J Cancer
, vol.38
, pp. 22-32
-
-
Grover, J.K.1
Vats, K.2
-
205
-
-
51649117633
-
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
-
Von Lillenfeld TM, Hahn AC, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008;81:247-252.
-
(2008)
Eur J Haematol
, vol.81
, pp. 247-252
-
-
Von Lillenfeld, T.M.1
Hahn, A.C.2
Furkert, K.3
-
206
-
-
34848879192
-
Review of thalidomide in the treatment of newly diagnosed multiple myeloma
-
Cavello F, Boccadoro M, Palumbo A. Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag 2007;3:543-552.
-
(2007)
Ther Clin Risk Manag
, vol.3
, pp. 543-552
-
-
Cavello, F.1
Boccadoro, M.2
Palumbo, A.3
-
207
-
-
77955461166
-
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case match-study
-
Offidani M, Leoni P, Bringhen S, et al. Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case match-study. Leuk Lymphoma 2010;51:1444-1449.
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 1444-1449
-
-
Offidani, M.1
Leoni, P.2
Bringhen, S.3
-
208
-
-
33747174832
-
Thalidomide metabolism and hydrolysis: mechanisms and implications
-
Lepper ER, Smith NF, Cox MC, et al. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 2006;7:677-685.
-
(2006)
Curr Drug Metab
, vol.7
, pp. 677-685
-
-
Lepper, E.R.1
Smith, N.F.2
Cox, M.C.3
-
209
-
-
0032922147
-
Thalidomide S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide
-
Zeldis JB, Williams BA, Thomas SD, et al. Thalidomide S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-330.
-
(1999)
Clin Ther
, vol.21
, pp. 319-330
-
-
Zeldis, J.B.1
Williams, B.A.2
Thomas, S.D.3
-
210
-
-
49749133938
-
RevAssist: a comprehensive risk minimization program for preventing fetal exposure to lenalidomide
-
Castaneda CP, Zeldis JB, Feeman J, et al. RevAssist: a comprehensive risk minimization program for preventing fetal exposure to lenalidomide. Drug Saf 2008;31:743-752.
-
(2008)
Drug Saf
, vol.31
, pp. 743-752
-
-
Castaneda, C.P.1
Zeldis, J.B.2
Feeman, J.3
-
211
-
-
63949087792
-
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
-
Kumar G, Lau H, Laskin O. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 2009;63:1171-1175.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 1171-1175
-
-
Kumar, G.1
Lau, H.2
Laskin, O.3
-
212
-
-
77249144468
-
Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells
-
Bairey O, Vanichkin A, Shpilberg O. Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol 2010;32:e77-e85.
-
(2010)
Int J Lab Hematol
, vol.32
, pp. e77-e85
-
-
Bairey, O.1
Vanichkin, A.2
Shpilberg, O.3
-
213
-
-
70449637501
-
Arsenic trioxide as first line treatment for acute promyelocytic leukemia
-
Leu L, Mohassel L. Arsenic trioxide as first line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm 2009;66:1913-1918.
-
(2009)
Am J Health Syst Pharm
, vol.66
, pp. 1913-1918
-
-
Leu, L.1
Mohassel, L.2
-
214
-
-
68449096176
-
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells
-
Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma 2009;50:974-984.
-
(2009)
Leuk Lymphoma
, vol.50
, pp. 974-984
-
-
Dong, H.1
Chen, L.2
Chen, X.3
-
216
-
-
84895322387
-
Proteasome inhibitors
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Molineaux CJ, Crews CM. Proteasome inhibitors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:486-490.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 486-490
-
-
Molineaux, C.J.1
Crews, C.M.2
-
217
-
-
33644845743
-
Crystal structure of the boronic acidbased proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
-
Groll M, Berkers CR, Ploegh HL, et al. Crystal structure of the boronic acidbased proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-456.
-
(2006)
Structure
, vol.14
, pp. 451-456
-
-
Groll, M.1
Berkers, C.R.2
Ploegh, H.L.3
-
218
-
-
84971263917
-
Monoclonal antibodies
-
In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
-
Robinson MK, Borghaci H, Adams GP, et al. Monoclonal antibodies. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:537-548.
-
(2008)
Cancer: Principles and Practice of Oncology
, pp. 537-548
-
-
Robinson, M.K.1
Borghaci, H.2
Adams, G.P.3
-
219
-
-
77951936254
-
Monoclonal antibodies in the treatment of colorectal cancer: a review
-
Tol J, Punt CJ. Monoclonal antibodies in the treatment of colorectal cancer: a review. Clin Ther 2010;32:437-453.
-
(2010)
Clin Ther
, vol.32
, pp. 437-453
-
-
Tol, J.1
Punt, C.J.2
-
220
-
-
48149110374
-
The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)
-
Oei AL, Sweep FC, Thomas CM, et al. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008;32:1145-1157.
-
(2008)
Int J Oncol
, vol.32
, pp. 1145-1157
-
-
Oei, A.L.1
Sweep, F.C.2
Thomas, C.M.3
-
221
-
-
34848887261
-
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy
-
Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007;13:5544s-5548s.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5544s-5548s
-
-
Youssoufian, H.1
Hicklin, D.J.2
Rowinsky, E.K.3
-
222
-
-
0032824340
-
Monoclonal antibodies in cancer treatment: a review of recent progress
-
Alpaugh K, von Mehren M. Monoclonal antibodies in cancer treatment: a review of recent progress. BioDrugs 1999;12:209-236.
-
(1999)
BioDrugs
, vol.12
, pp. 209-236
-
-
Alpaugh, K.1
von Mehren, M.2
|